Improved Drug Patent Coordination: Agency Collaboration
This act aims to enhance cooperation between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) regarding patents for human drugs and biological products. This will lead to more consistent and efficient drug approval and patenting processes, potentially accelerating access to new therapies and providing greater legal certainty for pharmaceutical companies.
Key points
Establishment of an Interagency Task Force on Patents to facilitate information sharing between USPTO and FDA.
Improved access for patent examiners to FDA data on drugs, aiding in more accurate patent application assessments.
Implementation of confidentiality protocols to safeguard sensitive information from pharmaceutical companies.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.